Custom-fitted oral appliances reduce airway obstruction by physically repositioning the lower jaw or tongue forward during ...

NASDAQ: MTVA Lili Elston: Hello, and welcome to the Life Sciences Investor Forum. On behalf of OTC Markets and our co-host, Zacks Small Cap Research, we're very pleased you've joined us. The next ...

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong cash runway.

Dr. Austin Harris, a board-certified cardiothoracic anesthesiologist and the founder of NeuroRelief Ketamine & Infusion Therapy, is redefining the treatment landscape for patients grappling with ...

A new study reveals how the brain triggers the breakdown of stable fat cells that normally resist diet and exercise. This ...

The launch of Cloudcure's companion app marks the first step in the company's broader roadmap that will introduce additional clinical and technological capabilities. The company is developing features ...

Barclays 28th Annual Global Healthcare Conference March 11, 2026 2:00 PM EDTCompany ParticipantsAdam Steensberg - President ...

Kiosk-based cannabis access for seniors can be a positive development only if it is embedded within a medically supervised, ...

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

The Hoffman Process, popular with a growing number of CEOs and celebrities, is often described as ‘10 years of therapy in a week.’ ...

Medication can significantly improve the ability to initiate tasks, sustain attention, and complete responsibilities”— ...

More than half of Ozempic users prescribed the drug for obesity alone are stopping or reducing their doses within a year, ...